<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389376</url>
  </required_header>
  <id_info>
    <org_study_id>U01AT003566-01</org_study_id>
    <secondary_id>NIH grant # U01-AT0035661</secondary_id>
    <nct_id>NCT00389376</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Silymarin for Chronic Liver Diseases</brief_title>
  <acronym>SyNCH</acronym>
  <official_title>Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered Silymarin (Legalon) in Non-Cirrhotic Subjects With Chronic Hepatitis C or Non-Alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Complementary and Integrative Health (NCCIH)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of different dosages of
      silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo and 140 mg single dose + every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo and 280 mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo and 280mg every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo and 280 single dose + every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo and 560 mg single dose + every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo and 560 mg single dose + every 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo and 700 mg single dose + every 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>140 mg every 8 hours</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Legalon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>280 mg single dose</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Legalon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>280 mg single dose + every 8 hours</description>
    <arm_group_label>Group 4</arm_group_label>
    <other_name>Legalon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>560 mg single dose + every 8 hours</description>
    <arm_group_label>Group 5</arm_group_label>
    <other_name>Legalon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>560 mg single dose + every 8 hours</description>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Legalon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>280 mg every 8 hours</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Legalon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>700 mg single dose + every 8 hours</description>
    <arm_group_label>Group 7</arm_group_label>
    <other_name>Legalon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

        Subjects will be eligible for enrollment in this study if they meet the following criteria:

          -  Males or females; age at least 18 years at screening

          -  Abnormal ALT &gt; 65 IU/L (ie, approximately 1.5 x upper limit of normal)

          -  Negative urine pregnancy test (for women of childbearing potential) documented within
             the 24-hour period prior to the first dose of silymarin. Females of childbearing
             potential must be using two reliable forms of effective contraception during the study
             (while on drug and during follow-up)

          -  Hepatitis C virus (HCV) patients

          -  Previous treatment with any interferon-based therapy without sustained virological
             response.

          -  Serum HCV RNA above quantifiable level of detection by the assay, within 1 year of
             screening and after the end of therapy

          -  No antiviral therapy for at least 6 months prior to screening visit

          -  Nonalcoholic fatty liver disease (NAFLD) patients:

          -  Liver biopsy compatible with NAFLD within 3 years of screening

          -  Absence of other liver diseases by serological screening (anti-HCV, HBsAg), historical
             serological data from within 3 years of screening is acceptable.

          -  Before entering the study, subjects must agree not to consume alcohol for 48 hours
             prior to PK sampling days or while on study.

        Exclusion criteria

        Subjects with any of the following will not be eligible for participation:

          -  Use of silymarin or other milk thistle preparations within 30 days of screening

          -  Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol,
             within 30 days of screening. A multivitamin at standard doses will be allowed.

          -  Allergy/sensitivity to milk thistle or its preparations

          -  Use of silymarin or other antioxidants (as above) during the screening period.

          -  Use of warfarin, metronidazole or chronic use of acetaminophen greater than two gram
             per day

          -  Previous liver biopsy that demonstrated presence of cirrhosis

          -  Previous liver biopsy that demonstrated greater than or equal to 15% steatosis or
             evidence of steatohepatitis for HCV cohort

          -  Positive test for anti-HIV or HBsAg within 3 years of screening

          -  Positive urine drug screen for drugs of abuse at screening

          -  Alcohol consumption of more than one drink or equivalent (&gt;12 grams) per day. Patients
             who consumed more than this in the past must have maintained a level 12 grams or less
             per day of alcohol consumption for at least six months prior to screening.

          -  History of other chronic liver disease, including metabolic diseases, documented by
             appropriate test(s)

          -  Women with ongoing pregnancy or breast-feeding, or contemplating pregnancy

          -  Platelet count &lt;130,000 cells/mm3.

          -  Serum creatinine level &gt;1.5 times the upper limit of normal at screening, or CrCl 60
             cc/min, or currently on dialysis. The creatinine clearance (CrCl) will be calculated
             according to Cockcroft-Gault.

          -  Evidence of alcohol or drug abuse within 6 months prior to screening

          -  Evidence of decompensated liver disease defined as any of the following: serum albumin
             &lt;3.2 g/dl, total bilirubin &gt; 1.5 mg/dl, or PT/INR &gt; 1.3 times normal at screening, or
             history or presence of ascites or encephalopathy, or bleeding from esophageal varices

          -  History or other evidence of severe illness or any other conditions that would make
             the patient, in the opinion of the investigator, unsuitable for the study (such as
             poorly controlled psychiatric disease, coronary artery disease, or active
             gastrointestinal conditions that might interfere with drug absorption)

          -  History of immunologically mediated disease (e.g., inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hepatitis,
             autoimmune hemolytic anemia, severe psoriasis, rheumatoid arthritis) that could affect
             inflammatory biomarkers

          -  History of solid organ or bone marrow transplantation

          -  History of thyroid disease poorly controlled on prescribed medications

          -  Use of oral steroids within 30 days prior to screening

          -  Concurrent medications that are CYP3A4 inducers

          -  Inability or unwillingness to provide informed consent or abide by the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>K. Rajender Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nezam Afdhal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Fried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh, Graduate School of Public Health</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2006</study_first_submitted>
  <study_first_submitted_qc>October 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2006</study_first_posted>
  <last_update_submitted>February 15, 2008</last_update_submitted>
  <last_update_submitted_qc>February 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>SyNCH Steering Committee</name_title>
    <organization>NCCAM/NIDDK/UNC/UPenn/TJU/BIDMC/UPitt</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

